121 related articles for article (PubMed ID: 22952737)
1. Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
Ma W; Lu S; Pan P; Sadatmousavi P; Yuan Y; Chen P
PLoS One; 2012; 7(8):e43684. PubMed ID: 22952737
[TBL] [Abstract][Full Text] [Related]
2. Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.
Wu Y; Sadatmousavi P; Wang R; Lu S; Yuan YF; Chen P
Int J Nanomedicine; 2012; 7():3221-33. PubMed ID: 22802684
[TBL] [Abstract][Full Text] [Related]
3. Molecular binding of self-assembling peptide EAK16-II with anticancer agent EPT and its implication in cancer cell inhibition.
Lu S; Wang H; Sheng Y; Liu M; Chen P
J Control Release; 2012 May; 160(1):33-40. PubMed ID: 22465389
[TBL] [Abstract][Full Text] [Related]
4. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine.
Fung SY; Yang H; Chen P
PLoS One; 2008 Apr; 3(4):e1956. PubMed ID: 18398476
[TBL] [Abstract][Full Text] [Related]
5. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis.
Bawa R; Fung SY; Shiozaki A; Yang H; Zheng G; Keshavjee S; Liu M
Nanomedicine; 2012 Jul; 8(5):647-54. PubMed ID: 21889478
[TBL] [Abstract][Full Text] [Related]
6. Histidine-Rich Cell-Penetrating Peptide for Cancer Drug Delivery and Its Uptake Mechanism.
Zhang L; Xu J; Wang F; Ding Y; Wang T; Jin G; Martz M; Gui Z; Ouyang P; Chen P
Langmuir; 2019 Mar; 35(9):3513-3523. PubMed ID: 30673275
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application.
Masood F; Chen P; Yasin T; Fatima N; Hasan F; Hameed A
Mater Sci Eng C Mater Biol Appl; 2013 Apr; 33(3):1054-60. PubMed ID: 23827542
[TBL] [Abstract][Full Text] [Related]
8. Release of hydrophobic anticancer drug from a newly designed self-assembling peptide.
Wu M; Ye Z; Liu Y; Liu B; Zhao X
Mol Biosyst; 2011 Jun; 7(6):2040-7. PubMed ID: 21491031
[TBL] [Abstract][Full Text] [Related]
9. Interaction of a self-assembling peptide with oligonucleotides: complexation and aggregation.
Wang M; Law M; Duhamel J; Chen P
Biophys J; 2007 Oct; 93(7):2477-90. PubMed ID: 17545233
[TBL] [Abstract][Full Text] [Related]
10. Structural Plasticity of EAK-16 Peptide Inducing Vesicle Membrane Leakage.
Majid A; Naz F; Khaskheli MH
Protein Pept Lett; 2020; 27(8):801-807. PubMed ID: 32003653
[TBL] [Abstract][Full Text] [Related]
11. Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems.
Dan VM; Varghese TS; Viswanathan G; Baby S
Curr Cancer Drug Targets; 2020; 20(1):33-46. PubMed ID: 31560288
[TBL] [Abstract][Full Text] [Related]
12. Arginine-rich ionic complementary peptides as potential drug carriers: Impact of peptide sequence on size, shape and cell specificity.
Wan Z; Lu S; Zhao D; Ding Y; Chen P
Nanomedicine; 2016 Aug; 12(6):1479-88. PubMed ID: 26949161
[TBL] [Abstract][Full Text] [Related]
13. Excited state proton transfer dynamics of an eminent anticancer drug, ellipticine, in octyl glucoside micelle.
Gavvala K; Koninti RK; Sengupta A; Hazra P
Phys Chem Chem Phys; 2014 Jul; 16(28):14953-60. PubMed ID: 24931633
[TBL] [Abstract][Full Text] [Related]
14. Self/co-assembling peptide, EAR8-II, as a potential carrier for a hydrophobic anticancer drug pirarubicin (THP)--characterization and in-vitro delivery.
Sadatmousavi P; Chen P
Int J Mol Sci; 2013 Nov; 14(12):23315-29. PubMed ID: 24287908
[TBL] [Abstract][Full Text] [Related]
15. Design and Characterization of a Multifunctional pH-Triggered Peptide C8 for Selective Anticancer Activity.
Lu S; Bennett WF; Ding Y; Zhang L; Fan HY; Zhao D; Zheng T; Ouyang PK; Li J; Wu Y; Xu W; Chu D; Yuan Y; Heerklotz H; Karttunen M; Chen P
Adv Healthc Mater; 2015 Dec; 4(17):2709-18. PubMed ID: 26474414
[TBL] [Abstract][Full Text] [Related]
16. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid-model membrane interactions with branched polypeptide conjugates of a hepatitis A virus peptide epitope.
Nagy IB; Alsina MA; Haro I; Reig F; Hudecz F
Bioconjug Chem; 2000; 11(1):30-8. PubMed ID: 10639082
[TBL] [Abstract][Full Text] [Related]
18. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers.
Wang F; Chen J; Dai W; He Z; Zhai D; Chen W
Acta Pharm; 2017 Sep; 67(3):357-371. PubMed ID: 28858837
[TBL] [Abstract][Full Text] [Related]
20. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
